Business
Fennec Pharmaceuticals commercializes PEDMARK to reduce cisplatin-induced hearing loss in pediatric cancer patients.
Fennec's PEDMARK revenue declined and the company returned to loss, exposing its dependence on a single oncology-support product and limited commercial scale.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 6.1%Watch
- Profitability — The net loss widened from $436K to $9.741MWatch
- Cash flow — Operating cash flow turned negative at an outflow of $12.473M from $26.98MWatch
- Margins — Operating margin contracted 1947 bps to -14.07%Watch
- Accounting — Single-product commercialization riskWatch
- Insiders — 0 purchases and 21 salesWatch
Where the revenue comes from
Fiscal 2025, as FENNEC PHARMACEUTICALS INC. reports it. History and quarterly detail are in the app.
- PEDMARK$44.6M
Leadership changes
From FENNEC PHARMACEUTICALS INC.'s own filings, the day they're filed.
- Rostislav Raykov · Directors · departureeff. 2026-04-27
- Jeffrey S. Hackman · CEO · appointmenteff. 2024-08-05
- Rostislav Raykov · Chief Executive Officer · departureeff. 2024-08-05
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-06-10
- 8-K · Company announcement2026-05-22
- 8-K · Company announcement2026-05-18
- 10-Q · Quarterly report2026-05-14
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about FENNEC PHARMACEUTICALS INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.